Literature DB >> 11438904

Congenital lymphocytic choriomeningitis virus infection: decade of rediscovery.

L L Barton1, M B Mets.   

Abstract

Lymphocytic choriomeningitis virus (LCMV) is an underdiagnosed fetal teratogen. This diagnosis should be considered for infants and children with unexplained hydrocephalus, micro- or macrocephaly, intracranial calcifications, chorioretinitis, and nonimmune hydrops. The immunofluorescent antibody test is the only reasonable, commercially available, screening diagnostic tool. The differential diagnosis of congenital LCMV infection includes toxoplasmosis, rubella, cytomegalovirus, herpes simplex virus, enteroviruses, human parvovirus B19 [corrected], and syphilis. The infection has also been misdiagnosed as various neurologic, ophthalmologic, and chromosomal syndromes. Further research, to determine the prevalence of this infection in human and rodent populations, and prospective studies, to delineate the clinical spectrum of congenital infection, are needed. The public and members of the medical profession should be made aware of the hazard that wild, pet, and laboratory rodents pose to pregnant women.

Entities:  

Mesh:

Year:  2001        PMID: 11438904     DOI: 10.1086/321897

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  44 in total

1.  Critical role for glial cells in the propagation and spread of lymphocytic choriomeningitis virus in the developing rat brain.

Authors:  Daniel J Bonthius; Jolonda Mahoney; Michael J Buchmeier; Bahri Karacay; Derek Taggard
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

2.  Dysregulation of protein modification by ISG15 results in brain cell injury.

Authors:  Kenneth J Ritchie; Michael P Malakhov; Christopher J Hetherington; Liming Zhou; Marie-Terese Little; Oxana A Malakhova; Jack C Sipe; Stuart H Orkin; Dong-Er Zhang
Journal:  Genes Dev       Date:  2002-09-01       Impact factor: 11.361

3.  Altered central nervous system gene expression caused by congenitally acquired persistent infection with lymphocytic choriomeningitis virus.

Authors:  Stefan Kunz; Jillian M Rojek; Amanda J Roberts; Dorian B McGavern; Michael B A Oldstone; Juan Carlos de la Torre
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

4.  Sodium hydrogen exchangers contribute to arenavirus cell entry.

Authors:  Masaharu Iwasaki; Nhi Ngo; Juan C de la Torre
Journal:  J Virol       Date:  2013-10-30       Impact factor: 5.103

5.  Development of multiplex PCRs for detection of common viral pathogens and agents of congenital infections.

Authors:  C J McIver; C F H Jacques; S S W Chow; S C Munro; G M Scott; J A Roberts; M E Craig; W D Rawlinson
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

6.  Efficient Interaction between Arenavirus Nucleoprotein (NP) and RNA-Dependent RNA Polymerase (L) Is Mediated by the Virus Nucleocapsid (NP-RNA) Template.

Authors:  Masaharu Iwasaki; Nhi Ngo; Beatrice Cubitt; Juan C de la Torre
Journal:  J Virol       Date:  2015-03-11       Impact factor: 5.103

7.  Identification and Mechanism of Action of a Novel Small-Molecule Inhibitor of Arenavirus Multiplication.

Authors:  Nhi Ngo; Kristina Schimmelpfeng Henthorn; Maria Isabel Cisneros; Beatrice Cubitt; Masaharu Iwasaki; Juan C de la Torre; Juan Lama
Journal:  J Virol       Date:  2015-08-19       Impact factor: 5.103

8.  Targeting Schwann cells by nonlytic arenaviral infection selectively inhibits myelination.

Authors:  Anura Rambukkana; Stefan Kunz; Jenny Min; Kevin P Campbell; Michael B A Oldstone
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

Review 9.  Lymphocytic choriomeningitis virus: an underrecognized cause of neurologic disease in the fetus, child, and adult.

Authors:  Daniel J Bonthius
Journal:  Semin Pediatr Neurol       Date:  2012-09       Impact factor: 1.636

Review 10.  Reverse genetics approaches to combat pathogenic arenaviruses.

Authors:  Juan C de la Torre
Journal:  Antiviral Res       Date:  2008-09-07       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.